Cholinergic deficiency and frontal dysfunction in Parkinson's disease

To investigate the influence of Central cholinergic deficit on cognitive function in Parkinson's disease (PD), we compared the neuropsychological performance of a group of 20 patients who were treated with anticholinergic drugs (mean daily dose, 10.2mg) with that of a group of 20 patients who received no anticholinergics. The two groups were matched for all the variables of parkinsonism and levodopa therapy. At the dose used, there was no significant difference between the two groups of patients for intellectual, visuospatial, instrumental, and memory function. In contrast, in the group that received anticholinergics severe impairment was observed on tests believed to assess frontal lobe function. These results suggest that the lesion of the ascending cholinergic neurons, which has been demonstrated post mortem in PD, may play a role in the subcorticofrontal behavioral impairment of this disease.

[1]  Y. Agid,et al.  Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat , 1985, Brain Research.

[2]  D. Safer,et al.  The central effects of scopolamine in man. , 1971, Biological psychiatry.

[3]  R. Bartus,et al.  Short-term memory in the rhesus monkey: Disruption from the anti-cholinergic scopolamine , 1976, Pharmacology Biochemistry and Behavior.

[4]  K. Wesnes,et al.  Drugs as research tools in psychology: cholinergic drugs and information processing. , 1984, Neuropsychobiology.

[5]  Winford A. Gordon,et al.  Effects of scopolamine, pentobarbital, and amphetamine on radial arm maze performance in the rat , 1980, Pharmacology Biochemistry and Behavior.

[6]  E. Perry.  The cholinergic hypothesis--ten years on. , 1986, British medical bulletin.

[7]  Arthur L. Benton,et al.  Differential behavioral effects in frontal lobe disease , 1968 .

[8]  H. Nelson.  A Modified Card Sorting Test Sensitive to Frontal Lobe Defects , 1976, Cortex.

[9]  H. Alpern,et al.  Short-term memory: facilitation and disruption with cholinergic agents. , 1973, Physiology & behavior.

[10]  H. Weingartner,et al.  Human serial learning: enhancement with arecholine and choline impairment with scopolamine. , 1978, Science.

[11]  J. M. Whitehouse.  EFFECTS OF ATROPINE ON DISCRIMINATION LEARNING IN THE RAT. , 1964, Journal of Comparative and Physiological Psychology.

[12]  F Lhermitte,et al.  Cholinergic‐dependent cognitive deficits in Parkinson's disease , 1987, Annals of neurology.

[13]  D. Olton,et al.  Lesions in nucleus basalis magnocellularis and medial septal area of rats produce qualitatively similar memory impairments , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[15]  J. Saint-Cyr,et al.  Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. , 1986, Brain : a journal of neurology.

[16]  B. Pillon,et al.  Human autonomy and the frontal lobes. Part I: Imitation and utilization behavior: A neuropsychological study of 75 patients , 1986, Annals of neurology.

[17]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[18]  Y. Agid,et al.  [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation]. , 1985, Revue neurologique.

[19]  Yves Agid,et al.  A subcortico-cortical cholinergic system is affected in Parkinson's disease , 1983, Brain Research.

[20]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[21]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[22]  D. Drachman,et al.  Memory and cognitive function in man , 1977, Neurology.

[23]  Y. Agid,et al.  [The L-dopa test in Parkinson's disease]. , 1985, Revue neurologique.

[24]  P. Tariot,et al.  Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations , 1988, Brain Research Reviews.

[25]  L. Hartley,et al.  The effects of scopolamine upon verbal memory: evidence for an attentional hypothesis. , 1985, Acta psychologica.

[26]  L. Squire.  Effects of pretrial and posttrial administration of cholinergic and anticholinergic drugs on spontaneous alternation. , 1969, Journal of comparative and physiological psychology.

[27]  F Lhermitte,et al.  Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment , 1989, Neurology.

[28]  Gwenn S. Smith,et al.  Scopolamine Reduces Frontal Cortex Perfusion , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[30]  Walter Schneider,et al.  Controlled and Automatic Human Information Processing: 1. Detection, Search, and Attention. , 1977 .

[31]  Y. Agid,et al.  Choline acetyltransferase activity and [ 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions , 1990, Neuroscience.

[32]  M. Kopelman,et al.  Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. , 1988, Brain : a journal of neurology.

[33]  A. Luria.  Higher Cortical Functions in Man , 1980, Springer US.

[34]  R. Morris,et al.  The Cholinergic Hypothesis of Memory: A Review of Animal Experiments , 1988 .

[35]  F Lhermitte,et al.  Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease , 1986, Neurology.